Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Allal

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinomaFabienne Thomas, Philippe Rochaix, Adil Benlyazid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2005
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinomaJ P Delord, C Allal, M Canal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysisFlorence Dalenc, Sophie F Doisneau-Sixou, Ben C Allal, et al.
British Journal of Clinical Pharmacology|February 28, 2019
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patientsFélicien Le Louedec, Catherine Alix-Panabières, Thierry Lafont, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinomaFabienne Thomas, Philippe Rochaix, Adil Benlyazid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2005
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinomaJ P Delord, C Allal, M Canal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysisFlorence Dalenc, Sophie F Doisneau-Sixou, Ben C Allal, et al.
British Journal of Clinical Pharmacology|February 28, 2019
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patientsFélicien Le Louedec, Catherine Alix-Panabières, Thierry Lafont, et al.
Pageof 3